FAGR Fagron SA

Record revenue of €209 million in first quarter reflecting 15% topline growth

Record revenue of €209 million in first quarter reflecting 15% topline growth

Regulated information - inside information

Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET

Record revenue of €209 million in first quarter reflecting 15% topline growth

Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024.

Key Highlights

  • Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regions
  • Organic growth at CER of 12.3% reflects the continued strong performance in North America and robustness in EMEA
  • Global operational excellence initiatives on track and yielding efficiencies
  • Integration of LSP and Parma Produkt progressing as planned; remain committed to disciplined acquisition strategy
  • FY 2024 outlook of high single-digit organic sales growth and improvement in profitability reaffirmed



Rafael Padilla, CEO of Fagron:         

“I am pleased to report another excellent quarter for Fagron with our teams delivering commendable results. The market dynamics across our regions are challenging, yet Fagron’s business model proves resilient, affirming our unique global positioning and leadership.

Our organic growth is driven by our focused commercial strategy, operational efficiencies, and the successful implementation of our global excellence initiatives. North America in particular has seen record growth with strong underlying demand at both FSS and Anazao. In EMEA, we have delivered a strong performance despite the impact of the change in reimbursement policy in Poland, as other markets compensated adequately, further highlighting the strength of our diversification strategy. In Latin America, growth has slowed slightly this quarter due to seasonal effects, while the competitive and consumer dynamics remained unchanged.

We are on track with the integration of our recent acquisitions and remain committed to exploring market opportunities globally to further strengthen our position.

Overall, we are confident in our outlook and reiterate our FY 2024 and mid-term guidance, as we continue to capitalize on growth opportunities that support our strategic objectives.”

Please open the link below for the full press release:

Attachment



EN
11/04/2024

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Frank Claassen
  • Frank Claassen
FAGR FAGRON SA

Fagron - Compounding for growth

•    New 40p report: Fagron is an excellent play on the structural growth drivers of personalized medication (e.g. demographics, drug shortages). •    It has high visibility on high single digit organic growth and in combination with Buy-and-build this offers double digit EBITDA growth.•    We reiterate our Buy with a TP of EUR 24 (was EUR 23) based on our SOTP and DCF on the back of 2% higher EBITDA estimates following Q1.

04/22/24 April 22, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron Growth engine keeps running

We updated our model following Fagron's recent 1Q24 update. While our prior estimates for FY24 and beyond largely remain in place, we pay special attention to Fagron's North American compounding services (CS) business (Boston/Wichita + Anazao), as well as the impact of the recent Polish regulatory change. Overall, our valuation continues to point to a TP of € 22, hence we maintain a Buy rating.

04/15/24 April 15, 2024 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publishes agenda for 2024 annual shareholders meeting and extra...

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial stateme...

April 12, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
FAGR FAGRON SA

Fagron FIRST LOOK: 1Q24 conference call feedback

Following our earlier note on the 1Q24 results (LINK), we share our main takeaways from the conference call hosted by Fagron to discuss its 1Q24 results.

04/11/24 April 11, 2024 1 EN
Oliver Metzger
  • Oliver Metzger
ROG Roche Holding L...
OSE OSE Immunothera... ... (+14)

ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024

Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...

ROG ROCHE HOLDING LTD
OSE OSE IMMUNOTHERAPEUTICS SA
NOVN NOVARTIS AG
TFI TELEVISION FRANCAISE 1 SA
GXI GERRESHEIMER AG
FAGR FAGRON SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
SAN SANOFI
SLIGR SLIGRO FOOD GROUP N.V.
AZN ASTRAZENECA PLC
ALVGO VOGO SA
GSK GSK PLC
NOVO B NOVO NORDISK A/S
04/11/24 April 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch